SELLAS Life Sciences Group (NASDAQ:SLS) Announces Quarterly Earnings Results

SELLAS Life Sciences Group (NASDAQ:SLS) announced its earnings results on Tuesday. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01, FiscalAI reports.

SELLAS Life Sciences Group Stock Down 0.6%

Shares of NASDAQ:SLS traded down $0.03 during trading on Tuesday, hitting $5.22. 2,913,681 shares of the company traded hands, compared to its average volume of 7,224,496. The stock has a market capitalization of $963.26 million, a price-to-earnings ratio of -20.88 and a beta of 2.24. The business’s fifty day moving average is $4.95 and its 200-day moving average is $3.61. SELLAS Life Sciences Group has a one year low of $1.36 and a one year high of $6.14.

Hedge Funds Weigh In On SELLAS Life Sciences Group

Institutional investors have recently made changes to their positions in the stock. Beacon Pointe Advisors LLC bought a new position in shares of SELLAS Life Sciences Group during the fourth quarter valued at approximately $38,000. Stifel Financial Corp acquired a new position in shares of SELLAS Life Sciences Group during the fourth quarter worth approximately $49,000. Boothbay Fund Management LLC acquired a new position in shares of SELLAS Life Sciences Group during the fourth quarter worth approximately $52,000. BNP Paribas Financial Markets boosted its position in shares of SELLAS Life Sciences Group by 89.2% during the third quarter. BNP Paribas Financial Markets now owns 19,724 shares of the company’s stock worth $32,000 after buying an additional 9,299 shares during the period. Finally, Great Valley Advisor Group Inc. acquired a new position in shares of SELLAS Life Sciences Group during the second quarter worth approximately $44,000. 17.38% of the stock is owned by institutional investors.

Analysts Set New Price Targets

SLS has been the subject of several research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a report on Tuesday, April 21st. Maxim Group boosted their price objective on SELLAS Life Sciences Group from $7.00 to $10.00 and gave the company a “buy” rating in a report on Thursday, March 12th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, SELLAS Life Sciences Group has an average rating of “Hold” and a consensus price target of $10.00.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.